Article
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 May 2007
Massarelli Erminia, Varella-Garcia Marileila, Tang Ximing, Xavier Ana C, Ozburn Natalie C, Liu Diane D, Bekele Benjamin N, Herbst Roy S, Wistuba Ignacio I
Abstract excerpt
PURPOSE: EGFR gene mutations and increased EGFR copy number have been associated with favorable response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in patients with non-small-cell lung cancer (NSCLC). In contrast, KRAS mutation has been shown to predict poor response to such therapy. We tested the utility of combinations of these three markers in predicting response and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.